Overview

Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100

Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100
Phase:
Phase 1
Details
Lead Sponsor:
BioVersys AG
Collaborator:
CW-Research and Management GmbH
Treatments:
Rifabutin